SOX9 Inhibits the Progression of Osteonecrosis of the Femoral Head via the Activation of the Wnt/Beta-Catenin Pathway

References

• Abramoff B, Caldera FE. Osteoarthritis: pathology, diagnosis, and treatment options. Med Clin North Am. 2020;104(2):1–8. doi:10.1016/j.mcna.2019.10.007.
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cooper K, Harris P, Picot J, Rose M. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2016;20(34):1–222. doi:10.3310/hta20340.
   Google Scholar
• Peat G, Thomas MJ. Osteoarthritis year in review 2020: epidemiology & therapy. Osteoarthritis Cartilage. 2021;29(2):180–189. doi:10.1016/j.joca.2020.10.007.
   PubMed Web of Science ®Google Scholar
• Katz JN, Arant KR, Loeser RF. Diagnosis and treatment of hip and knee osteoarthritis: a review. JAMA. 2021;325(6):568–578. doi:10.1001/jama.2020.22171.
   PubMed Web of Science ®Google Scholar
• George G, Lane JM. Osteonecrosis of the femoral head. J Am Acad Orthop Surg Glob Res Rev. 2022;6:e21.00176.
   PubMedGoogle Scholar
• Cohen-Rosenblum A, Cui Q. Osteonecrosis of the femoral head. Orthop Clin North Am. 2019;50(2):139–149. doi:10.1016/j.ocl.2018.10.001.
   PubMed Web of Science ®Google Scholar
• Zhao D, Zhang F, Wang B, et al. Guidelines for clinical diagnosis and treatment of osteonecrosis of the femoral head in adults (2019 version). J Orthop Translat. 2020;21:100–110. doi:10.1016/j.jot.2019.12.004.
   PubMed Web of Science ®Google Scholar
• Petek D, Hannouche D, Suva D. Osteonecrosis of the femoral head: pathophysiology and current concepts of treatment. EFORT Open Rev. 2019;4(3):85–97. doi:10.1302/2058-5241.4.180036.
   PubMed Web of Science ®Google Scholar
• Hoggard TM, Chen DQ, Quinlan ND, Bell JE, Werner BC, Cui Q. Outcomes following total hip arthroplasty for osteonecrosis of the femoral head in patients on hemodialysis. J Bone Joint Surg Am. 2022;104(Suppl 2):90–94. doi:10.2106/JBJS.20.00352.
   PubMed Web of Science ®Google Scholar
• Zhao D, Xie H, Xu Y, et al. Management of osteonecrosis of the femoral head with pedicled iliac bone flap transfer: a multicenter study of 2190 patients. Microsurgery. 2017;37(8):896–901. doi:10.1002/micr.30195.
   PubMed Web of Science ®Google Scholar
• Zhang YL, Yin JH, Ding H, Zhang W, Zhang CQ, Gao YS. Vitamin K2 prevents glucocorticoid-induced osteonecrosis of the femoral head in rats. Int J Biol Sci. 2016;12(4):347–358. doi:10.7150/ijbs.13269.
   PubMed Web of Science ®Google Scholar
• Chang C, Greenspan A, Gershwin M. The pathogenesis, diagnosis and clinical manifestations of steroid-induced osteonecrosis. J Autoimmun. 2020;110:102460.
   PubMed Web of Science ®Google Scholar
• Xie Y, Hu JZ, Shi ZY. MiR-181d promotes steroidinduced osteonecrosis of the femoral head by targeting SMAD3 to inhibit osteogenic differentiation of hBMSCs. Eur Rev Med Pharmacol Sci. 2018;22:4053–4062.
   PubMed Web of Science ®Google Scholar
• Zhao DW, Yu M, Hu K, et al. L. Prevalence of nontraumatic osteonecrosis of the femoral head and its associated risk factors in the Chinese population: results from a nationally representative survey. Chin Med J. 2015;128(21):2843–2850. doi:10.4103/0366-6999.168017.
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhu H, Wang Q, Feng Y, Zhang C. Inhibition of PERK signaling prevents against glucocorticoid-induced endotheliocyte apoptosis and osteonecrosis of the femoral head. Int J Biol Sci. 2020;16(4):543–552. doi:10.7150/ijbs.35256.
   PubMed Web of Science ®Google Scholar
• Nie Z, Chen S, Peng H. Glucocorticoid induces osteonecrosis of the femoral head in rats through GSK3β-mediated osteoblast apoptosis. Biochem Biophys Res Commun. 2019;511(3):693–699. doi:10.1016/j.bbrc.2019.02.118.
   PubMed Web of Science ®Google Scholar
• Fan ZQ, Bai SC, Xu Q, et al. Oxidative stress induced osteocyte apoptosis in steroid-induced femoral head necrosis. Orthop Surg. 2021;13(7):2145–2152. doi:10.1111/os.13127.
   PubMed Web of Science ®Google Scholar
• Güler-Yüksel M, Hoes JN, Bultink IEM, Lems WF. Glucocorticoids, inflammation and bone. Calcif Tissue Int. 2018;102(5):592–606. doi:10.1007/s00223-017-0335-7.
   PubMed Web of Science ®Google Scholar
• González-Martín JJ, Novella-Navarro M, Calvo-Aranda E, et al. Endothelial dysfunction and subclinical atheromatosis in patients with systemic sclerosis. Clin Exp Rheumatol. 2020;38:48–52.
   PubMed Web of Science ®Google Scholar
• Song H, Park KH. Regulation and function of SOX9 during cartilage development and regeneration. Semin Cancer Biol. 2020;67:12–23. doi:10.1016/j.semcancer.2020.04.008.
   PubMed Web of Science ®Google Scholar
• Javier BM, Yaeger R, Wang L, et al. Recurrent, truncating SOX9 mutations are associated with SOX9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma. Oncotarget. 2016;7(32):50875–50882. doi:10.18632/oncotarget.9682.
   PubMedGoogle Scholar
• Akiyama H. Transcriptional regulation in chondrogenesis by SOX9. Clinical Calcium. 2011;21:845–851.
   PubMedGoogle Scholar
• Tamamura Y, Katsube K, Mera H, Itokazu M, Wakitani S. Irx3 and Bmp2 regulate mouse mesenchymal cell chondrogenic ­differentiation in both a Sox9-dependent and-independent manner. J Cell Physiol. 2017;232(12):3317–3336. doi:10.1002/jcp.25776.
   PubMed Web of Science ®Google Scholar
• Cucchiarini M, Orth P, Madry H. Direct rAAV SOX9 administration for durable articular cartilage repair with delayed terminal differentiation and hypertrophy in vivo. J Mol Med (Berl). 2013;91(5):625–636.
   PubMed Web of Science ®Google Scholar
• Song Y, Du ZW, Ren M, et al. Significant associations of SOX9 gene polymorphism and gene expression with the risk of osteonecrosis of the femoral head in a Han Population in Northern China. Biomed Res Int. 2016;2016:1–11. doi:10.1155/2016/5695317.
   Web of Science ®Google Scholar
• Wang XS, Zhuang QY, Weng XS, Lin J, Qian WW. Etiological and clinical analysis of osteonecrosis of the femoral head in Chinese patients. Chin Med J (Engl). 2013;126:290–295.
   PubMed Web of Science ®Google Scholar
• Sun H, Zhang W, Yang N, et al. Activation of cannabinoid receptor 2 alleviates glucocorticoidinduced osteonecrosis of femoral head with osteogenesis and maintenance of blood supply. Cell Death Dis. 2021;12(11):1035. doi:10.1038/s41419-021-04313-3.
   PubMed Web of Science ®Google Scholar
• Hao YQ, Lu C, Zhang BG, Xu ZC, Guo H, Zhang GK. Identifying the potential differentially expressed miRNAs and mRNAs in osteonecrosis of the femoral head based on integrated analysis. CIA. 2021;16:187–202. doi:10.2147/CIA.S289479.
   Google Scholar
• Wang CH, Zang HM, Zhou DS. Bone morphogenetic protein-2 exhibits therapeutic benefts for osteonecrosis of the femoral head through induction of cartilage and bone cells. Exp Ther Med. 2018;15:4298–4308.
   PubMed Web of Science ®Google Scholar
• Chen CY, Du W, Rao SS, et al. Extracellular vesicles from human urine-derived stem cells inhibit glucocorticoid-induced osteonecrosis of the femoral head by transporting and releasing pro-angiogenic DMBT1 and anti-apoptotic TIMP1. Acta Biomater. 2020;111:208–220.
   PubMed Web of Science ®Google Scholar
• Okazaki S, Nagoya S, Matsumoto H, et al. TLR4 stimulation and corticosteroid interactively induce osteonecrosis of the femoral head in rat. J Orthop Res. 2016;34(2):342–345. doi:10.1002/jor.23008.
   PubMed Web of Science ®Google Scholar
• Huang G, Zhao G, Xia J, et al. FGF2 and FAM201A affect the development of osteonecrosis of the femoral head after femoral neck fracture. Gene. 2018;652:39–47. doi:10.1016/j.gene.2018.01.090.
   PubMed Web of Science ®Google Scholar
• Li H, Zhou X, Yu Z, Tian Y. Circ_0075825 promotes gastric cancer progression via adsorbing miR-432-5p to modulate SOX9. Clinics (Sao Paulo). 2022;77:100018. doi:10.1016/j.clinsp.2022.100018.
   PubMed Web of Science ®Google Scholar
• Tian H, Hou L, Xiong Y, Cheng Q. Dexmedetomidine upregulates microRNA-185 to suppress ovarian cancer growth via inhibiting the SOX9/Wnt/β-catenin signaling pathway. Cell Cycle. 2021;20(8):765–780. doi:10.1080/15384101.2021.1897270.
   PubMed Web of Science ®Google Scholar
• Topol L, Chen W, Song H, Day TF, Yang Y. Sox9 inhibits Wnt signaling by promoting β-catenin phosphorylation in the nucleus. J Biol Chem. 2009;284(5):3323–3333. doi:10.1074/jbc.M808048200.
   PubMed Web of Science ®Google Scholar
• Feng L, Yang ZM, Li YC, et al. Linc-ROR promotes mesenchymal stem cells chondrogenesis and cartilage formation via regulating SOX9 expression. Osteoarthr Cartil. 2021;29(4):568–578. doi:10.1016/j.joca.2020.12.020.
   PubMed Web of Science ®Google Scholar
• He X, Bougioukli S, Ortega B, Arevalo E, Lieberman JR, McMahon AP. Sox9 positive periosteal cells in fracture repair of the adult mammalian long bone. Bone. 2017;103:12–19. doi:10.1016/j.bone.2017.06.008.
   PubMed Web of Science ®Google Scholar
• Chen XJ, Shen YS, He MC, et al. Polydatin promotes the osteogenic differentiation of human bone mesenchymal stem cells by activating the BMP2-Wnt/β-catenin signaling pathway. Biomed Pharmacother. 2019;112:108746. doi:10.1016/j.biopha.2019.108746.
   PubMed Web of Science ®Google Scholar